Xeris Biopharma (NASDAQ:XERS) Earns “Buy” Rating from HC Wainwright
Xeris Biopharma (NASDAQ:XERS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $8.00 price target on the stock, up from their previous price target of $6.60. HC Wainwright’s price target suggests a potential upside […]
Xeris Biopharma (NASDAQ:XERS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $8.00 price target on the stock, up from their previous price target of $6.60. HC Wainwright’s price target suggests a potential upside […]
